首页123下页尾页 共 41 条记录, 当前第1/3页。
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
2013/12/25 12:00
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Repaglinide;   Drug: Metformin
Sponsor:   RenJi Hospital
Completed - verified January 2014
Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines
2013/5/25 12:00
Condition:   Type 2 Diabetes
Interventions:   Drug: Best medical treatment;   Procedure: gastric bypass;   Procedure: sleeve gastrectomy;   Drug: General interventions for all groups: blood presure;   Drug: General interventions for all groups: dysilipidemia;   Behavioral: General interventions for all groups: lifestyle
Sponsor:   Pontificia Universidad Catolica de Chile
Recruiting - verified October 2013
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
2013/2/20 12:00
Conditions:   Drug-Drug Interaction (DDI);   Healthy Subjects
Interventions:   Drug: ASP3652;   Drug: Gemfibrozil;   Drug: Repaglinide
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Europe BV
Completed - verified February 2013
A Pharmacokinetic Study to Compare repaglinide2mg and metforomin500mg Complex to Combination of Those Two Components.
2013/1/29 12:00
Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Repanorm M 2/500mg, Novonorm 2mg, Diabex 500mg
Sponsors:   Dalim BioTech Co., Ltd.;   Dalim BioTech Co., Ltd.
Not yet recruiting - verified January 2013
Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
2012/10/31 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: metformin;   Drug: metformin
Sponsors:   Novo Nordisk;   Novo Nordisk
Completed - verified October 2012
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
2012/10/31 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: isophane human insulin;   Drug: insulin
Sponsors:   Novo Nordisk;   Novo Nordisk
Completed - verified October 2012
Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
2012/10/16 12:00
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Sitagliptin;   Drug: Acarbose;   Drug: Repaglinide;   Drug: Glimepiride;   Drug: Gliclazide
Sponsors:   Merck;   Merck
Not yet recruiting - verified October 2012
Efficacy of Repaglinide in Subjects With Type 2 Diabetes
2012/10/1 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: glyburide;   Drug: placebo
Sponsors:   Novo Nordisk;   Novo Nordisk
Completed - verified October 2012
MK-3102 Phase III Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
2012/9/28 12:00
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Basal medication
Sponsors:   Merck;   Merck
Not yet recruiting - verified October 2012
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
2012/5/16 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: glyburide
Sponsors:   Novo Nordisk;   Novo Nordisk
Completed - verified May 2012
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes
2012/3/22 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: insulin NPH
Sponsor:   Novo Nordisk
Completed - verified March 2012
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
2012/1/23 12:00
Condition:   Parkinson Disease
Interventions:   Drug: BIA 9-1067;   Drug: repaglinide
Sponsor:   Bial - Portela C S.A.
Completed - verified February 2012
Observational Study of NovoNorm® in Subjects With Diabetes
2011/12/21 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: repaglinide
Sponsor:   Novo Nordisk
Completed - verified December 2011
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
2011/12/21 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: repaglinide
Sponsor:   Novo Nordisk
Completed - verified December 2011
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
2011/12/8 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: metformin;   Drug: repaglinide and metformin combination tablet
Sponsor:   Novo Nordisk
Completed - verified December 2011
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
2011/12/8 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: metformin;   Drug: repaglinide and metformin combination tablet
Sponsor:   Novo Nordisk
Completed - verified December 2011
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
2011/10/31 12:00
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: repaglinide
Sponsor:   Novo Nordisk
Completed - verified November 2011
Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea
2011/5/13 12:00
Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No treatment given
Sponsor:   Novo Nordisk
Not yet recruiting - verified May 2011
Pharmacokinetic Study to Characterize Individual Metabolic Profile
2010/7/9 12:00
Condition:   Healthy Volunteers
Intervention:   Drug: 10 parents drugs adminstration
Sponsors:   Institut National de la Santé Et de la Recherche Médicale, France;   Nuclear Energy Commission (CEA)
Recruiting - verified July 2010
Treatment of Latent Autoimmune Diabetes of the Adult
2010/6/8 12:00
Condition:   Diabetes
Interventions:   Drug: metformin+ NPH insulin;   Drug: metformin + sitagliptin +/- repaglinide
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified June 2010